Autolus Therapeutics Ltd (6A3Ay)

Currency in EUR
2.20
-0.06(-2.65%)
Closed·
6A3Ay is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.182.30
52 wk Range
1.014.80
Key Statistics
Bid/Ask
2.10 / 2.18
Prev. Close
2.26
Open
2.24
Day's Range
2.18-2.3
52 wk Range
1.01-4.8
Volume
5.6K
Average Volume (3m)
8.36K
1-Year Change
-46.08%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6A3Ay Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Autolus Therapeutics Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Autolus Therapeutics Ltd Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Compare 6A3Ay to Peers and Sector

Metrics to compare
6A3Ay
Peers
Sector
Relationship
P/E Ratio
0.0x−5.6x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.0x3.9x2.6x
Price / LTM Sales
0.0x9.5x3.2x
Upside (Analyst Target)
0.0%163.9%40.5%
Fair Value Upside
Unlock13.1%4.4%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

6A3Ay Income Statement

People Also Watch

51.670
SMR
+1.25%
38.330
ARQQ
-2.44%
75.49
OKLO
+1.20%
2.635
TSHA
+1.74%
142.03
FI
+1.39%

FAQ

What Stock Exchange Does Autolus Therapeutics Ltd Trade On?

Autolus Therapeutics Ltd is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Autolus Therapeutics Ltd?

The stock symbol for Autolus Therapeutics Ltd is "6A3Ay."

What Is the Autolus Therapeutics Ltd Market Cap?

As of today, Autolus Therapeutics Ltd market cap is 568.75M.

What Is Autolus Therapeutics Ltd's Earnings Per Share (TTM)?

The Autolus Therapeutics Ltd EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 6A3Ay a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Autolus Therapeutics Ltd Stock Split?

Autolus Therapeutics Ltd has split 0 times.

What is the current trading status of Autolus Therapeutics Ltd (6A3Ay)?

As of 25 Jul 2025, Autolus Therapeutics Ltd (6A3Ay) is trading at a price of 2.20, with a previous close of 2.26. The stock has fluctuated within a day range of 2.18 to 2.30, while its 52-week range spans from 1.01 to 4.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.